<DOC>
	<DOC>NCT01890577</DOC>
	<brief_summary>An observational study to describe the treatment of anaemia in patients with chronic kidney disease, who are receiving dialysis treatment at selected study centres in South Africa.</brief_summary>
	<brief_title>Study of South African Dialysis Patients</brief_title>
	<detailed_description>This multicentre, prospective, observational study will describe the treatment and clinical outcomes of of dialysis patients in South Africa. No formal hypothesis will be tested in this descriptive study. Eligible subjects will be receiving either peritoneal or haemodialysis, will have received Aranesp therapy between 3 and 6 months prior to enrolment into the study, do not need to be receiving Aranesp at the time of enrolment and will be followed for up to 12 months after commencement of Aranesp. Data to be collected includes ESA therapies, iron usage, relevant concomitant therapies, haemoglobin concentrations, other relevant clinical laboratory parameters and red cell transfusions.</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Adult patients undergoing chronic haemodialysis or peritoneal dialysis Commenced Aranesp therapy 36 months prior to enrolment Erythropoiesis stimulating agent (ESA) naive or treated with another ESA prior to commencing Aranesp Informed consent obtained Received Aranesp in an interventional study within 6 months prior to start of observation period Receive investigational product during the observation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Dialysis</keyword>
	<keyword>Erythropoiesis stimulating agent</keyword>
	<keyword>South Africa</keyword>
</DOC>